Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CVS Health Corporation (NYSE: CVS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission (SEC). These filings document material events, financial results, capital markets transactions, governance changes and legal developments that affect CVS Health and its shareholders.
Among the key documents are current reports on Form 8-K, which CVS Health uses to announce items such as quarterly and year-to-date financial results, updated financial guidance, and Investor Day presentations. For example, the company has filed Form 8-K reports furnishing press releases that discuss strategic priorities, revenue and earnings guidance, and non-GAAP measures like adjusted operating income and adjusted earnings per share, along with reconciliations to GAAP metrics.
Other Form 8-K filings describe governance actions, including the Board of Directors’ appointment of J. David Joyner, President and Chief Executive Officer, to the additional role of Chair of the Board. Capital markets activity is also reflected in filings that detail the issuance of senior notes under an Underwriting Agreement, including principal amounts, maturities, interest rates and references to the governing senior indenture and registration statement.
Filings further address legal and subsidiary matters, such as the disclosure that Omnicare, LLC, a wholly owned indirect subsidiary of CVS Health, and certain of its subsidiary entities voluntarily initiated chapter 11 proceedings under the U.S. Bankruptcy Code to address litigation-related monetary damages and other financial challenges. These documents outline the use of debtor-in-possession financing and the evaluation of restructuring options.
On Stock Titan, AI-powered tools summarize and highlight the contents of CVS Health’s SEC filings, helping readers quickly identify key points in lengthy documents such as 8-Ks, and providing context around financial measures, governance changes and risk-related disclosures.
CVS Health Corp executive Heidi B. Capozzi reported a tax-related share withholding transaction. On 11/30/2025, she surrendered 9,470 shares of CVS Health common stock at $80.36 per share, coded as an "F" transaction, meaning the shares were withheld to cover taxes due on the vesting and settlement of a restricted stock unit award.
After this transaction, she directly owned 11,415 shares of CVS Health common stock as an executive vice president and Chief People Officer. This event reflects administrative handling of equity compensation rather than an open-market sale.
CVS Health Corp (CVS) director Douglas H. Shulman reported a routine equity compensation transaction. On 11/20/2025, he acquired 1,652 shares of common stock at a price of $76.04 per share, recorded as an "A" (acquired) transaction.
These shares were issued as payment of a semi-annual retainer at the market price under the company’s 2017 Incentive Compensation Plan, reflecting standard board compensation rather than an open-market purchase. Following this grant, Shulman beneficially owns 5,929 shares of CVS Health common stock in direct ownership.
CVS Health Corporation director Guy P. Sansone reported receiving common stock as part of his board compensation. On 11/20/2025, he acquired 1,652 shares of CVS common stock at a price of $76.04 per share. The filing explains this stock was issued as payment of a semi-annual retainer at market price under the company’s 2017 Incentive Compensation Plan. Following this grant, Sansone beneficially owns 13,659.355 shares of CVS common stock in direct ownership.
CVS Health Corp (CVS)2,202.788 deferred stock units with a conversion price of $0 under the company’s 2017 Incentive Compensation Plan. These units were issued in connection with the deferral of a semi-annual retainer under the non-employee director compensation policy and are valued at the market price of $76.04 per underlying share of common stock. Each deferred stock unit will convert into one share of CVS common stock and will be issued when the director retires from the Board, as previously elected. Following this transaction, the director beneficially owns 8,080.2915 deferred stock units in direct form.
CVS Health (CVS) director equity grant reported
A CVS Health Corp director filed a Form 4 reporting receipt of 1,652 shares of common stock on 11/20/2025 at a price of $76.04 per share. These shares were issued as payment of a semi-annual board retainer at market price under the company’s 2017 Incentive Compensation Plan, meaning they represent routine director compensation in stock rather than cash.
Following this grant, the director beneficially owns 5,929 CVS common shares, held directly. The filing indicates this was a standard compensation-related issuance, not an open-market purchase or sale.
CVS Health Corp director reports deferred stock unit grant. A CVS Health Corp non-employee director filed a Form 4 reporting receipt of 2,021.9621 deferred stock units on 11/20/2025 under the company’s 2017 Incentive Compensation Plan. These units were issued in connection with the deferral of a semi-annual director retainer and valued at the market price of $76.04 per deferred stock unit.
Each deferred stock unit is to be converted into one share of CVS common stock and issued in the future, as elected by the reporting person. After this transaction, the director beneficially owns 4,613.3964 deferred stock units in direct form, reflecting accumulated deferred equity compensation rather than an open-market purchase or sale.
CVS Health (CVS) director J. Scott Kirby reported the receipt of additional company stock. On 11/20/2025, he acquired 1,652 shares of CVS Health common stock at a price of $76.04 per share. This was issued as payment of a semi-annual retainer under the company’s 2017 Incentive Compensation Plan, rather than a market purchase.
Following this transaction, Kirby beneficially owns 12,987 CVS Health common shares, held directly. The filing is made on Form 4 as he serves as a director of CVS Health and is required to report changes in his ownership of company equity.
CVS Health director equity activity: A CVS Health Corp director reported routine equity compensation on a Form 4 for 11/20/2025. The director acquired 591 shares of common stock at $76.04 per share, which were issued as payment of a semi-annual cash retainer under the company’s 2017 Incentive Compensation Plan.
The filing also shows an award of 1,775.3814 deferred stock units, representing deferral of a semi-annual retainer under the non-employee director compensation policy. After this transaction, the director holds 16,530.0615 deferred stock units, each convertible into one share of CVS common stock to be issued in the future as elected by the director.
CVS Health reported a Form 4 for a director reflecting routine equity compensation. On 11/20/2025, the director acquired 1,652.091 deferred stock units with each unit representing one share of CVS Health common stock. These units were issued for deferral of a semi-annual retainer under the company’s non-employee director compensation policy and were valued at the market price pursuant to the 2017 Incentive Compensation Plan. After this transaction, the director beneficially owned 40,053.5157 deferred stock units on a direct basis.
CVS Health Corp reported an insider equity transaction by a company director on a Form 4. On 11/20/2025, the director acquired 1,775 shares of CVS Health common stock, labeled as an acquisition, at a price of $76.04 per share. The filing explains that these shares were issued as payment of a semi-annual retainer at the market price under the company’s 2017 Incentive Compensation Plan, meaning they represent stock-based compensation rather than an open-market purchase. Following this transaction, the director directly owns 127,772 shares of CVS Health common stock.